MA34297B1 - Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation - Google Patents

Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation

Info

Publication number
MA34297B1
MA34297B1 MA35430A MA35430A MA34297B1 MA 34297 B1 MA34297 B1 MA 34297B1 MA 35430 A MA35430 A MA 35430A MA 35430 A MA35430 A MA 35430A MA 34297 B1 MA34297 B1 MA 34297B1
Authority
MA
Morocco
Prior art keywords
angiotensin
receptor antagonists
xanthine oxidase
association
oxidase inhibitors
Prior art date
Application number
MA35430A
Other languages
English (en)
Inventor
Sandro Giuliani
Francesco Melani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34297(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of MA34297B1 publication Critical patent/MA34297B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet une association de principes actifs, c'est-à-dire d'un inhibiteur de la xanthine oxydase avec un ou plusieurs antagonistes du récepteur de l'angiotensine II, des compositions pharmaceutiques comprenant lesdits principes actifs, destinée à être utilisée dans un traitement thérapeutique chez des humains ou des animaux, et des procédés pour sa préparation.
MA35430A 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation MA34297B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
PCT/EP2011/057438 WO2011141431A1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation

Publications (1)

Publication Number Publication Date
MA34297B1 true MA34297B1 (fr) 2013-06-01

Family

ID=42753377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35430A MA34297B1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation

Country Status (23)

Country Link
US (1) US20130131128A1 (fr)
EP (1) EP2568982B1 (fr)
JP (1) JP2013526503A (fr)
KR (1) KR20130101447A (fr)
CN (1) CN103037861A (fr)
AR (1) AR081376A1 (fr)
AU (1) AU2011252151A1 (fr)
BR (1) BR112012028887A2 (fr)
CA (1) CA2798573A1 (fr)
CL (1) CL2012003143A1 (fr)
CO (1) CO6640306A2 (fr)
EA (1) EA201201528A1 (fr)
EC (2) ECSP12012332A (fr)
IL (1) IL222927A0 (fr)
IT (1) IT1400311B1 (fr)
MA (1) MA34297B1 (fr)
MX (1) MX2012013054A (fr)
NZ (1) NZ603414A (fr)
PE (1) PE20130812A1 (fr)
SG (1) SG185474A1 (fr)
TW (1) TW201206432A (fr)
WO (1) WO2011141431A1 (fr)
ZA (1) ZA201209295B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028371B1 (fr) * 2014-11-06 2016-11-18 Bull Sas Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede
KR102284764B1 (ko) 2020-07-08 2021-08-04 주식회사 우드메탈 멀티빔구조를 통한 부속의 결속이 용이한 칸막이

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
CA2229000C (fr) 1991-02-21 2002-04-09 Sankyo Company, Limited Derives de 1-biphenylimidazole, leur preparation et leur utilisation therapeutique
TR200000458T1 (tr) 1998-06-19 2000-10-23 Teijin Limited 2-(3-siyano-4-izobütiloksifenil)-4-Metil-5-tiazolkarboksilik asit ve bunun üretilmesi için yöntem.
KR100656716B1 (ko) 2000-11-21 2006-12-13 상꾜 가부시키가이샤 의약 조성물
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
JP3874419B2 (ja) 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
WO2005027887A2 (fr) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Procedes et compositions permettant d'ameliorer la fonction endotheliale
EP1940397A4 (fr) * 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A Methodes de traitement de l'hypertension
JP2009516691A (ja) 2005-11-21 2009-04-23 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド Ｑｔ間隔延長およびこれに伴う疾病の治療
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Also Published As

Publication number Publication date
AU2011252151A1 (en) 2012-11-29
EA201201528A1 (ru) 2013-04-30
IL222927A0 (en) 2012-12-31
NZ603414A (en) 2014-03-28
ZA201209295B (en) 2013-08-28
US20130131128A1 (en) 2013-05-23
CL2012003143A1 (es) 2013-06-21
EP2568982B1 (fr) 2014-04-02
CN103037861A (zh) 2013-04-10
SG185474A1 (en) 2012-12-28
IT1400311B1 (it) 2013-05-24
EP2568982A1 (fr) 2013-03-20
CO6640306A2 (es) 2013-03-22
KR20130101447A (ko) 2013-09-13
JP2013526503A (ja) 2013-06-24
WO2011141431A1 (fr) 2011-11-17
BR112012028887A2 (pt) 2016-07-26
TW201206432A (en) 2012-02-16
CA2798573A1 (fr) 2011-11-17
PE20130812A1 (es) 2013-08-08
AR081376A1 (es) 2012-08-29
ITRM20100232A1 (it) 2011-11-11
ECSP12012331A (es) 2013-02-28
MX2012013054A (es) 2013-03-05
ECSP12012332A (es) 2013-02-28

Similar Documents

Publication Publication Date Title
Wong et al. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
EA201790950A1 (ru) Способы и композиции, в частности, для лечения синдрома дефицита внимания
MA34297B1 (fr) Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation
MA34106B1 (fr) Combinaison de composés organiques